



## PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology – Rydapt Prior Authorization Policy

- Rydapt® (midostaurin capsules – Novartis)

**REVIEW DATE:** 03/12/2025

### INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

## CIGNA NATIONAL FORMULARY COVERAGE:

### OVERVIEW

Rydapt, a tyrosine kinase inhibitor, is indicated in adults for the following uses:<sup>1</sup>

- **Acute myeloid leukemia, newly diagnosed, that is FMS-like tyrosine kinase 3 (FLT3) mutation-positive** as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Limitations of use: Rydapt is not indicated as a single-agent induction therapy for treatment of patients with acute myeloid leukemia.
- **Aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia.**

### Guidelines

Rydapt is discussed in the National Comprehensive Cancer Network (NCCN) guidelines:<sup>2</sup>

- **Acute Myeloid Leukemia:** NCCN guidelines (version 2.2025 – January 27, 2025) recommend Rydapt ± cytarabine ±daunorubicin among the treatment options for induction (category 1) and re-induction, consolidation, post-induction therapy, maintenance, and for relapsed/refractory disease for patients with FLT3-ITD/TKD mutation (category 2A).<sup>3</sup>
- **Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion:** NCCN guidelines (version 1.2025 – February 21, 2025) recommend Rydapt for patients with FGFR1 or FLT3 rearrangements in chronic phase or blast phase (category 2A).<sup>4</sup> Rydapt is also recommended for treatment in combination with

induction chemotherapy followed by allogeneic hematopoietic cell transplantation (if eligible) for lymphoid, myeloid or mixed lineage neoplasms with eosinophilia and *FGFR1* or *FLT3* rearrangements in blast phase (category 2A).

- **Systemic Mastocytosis:** NCCN guidelines (version 1.2025 – February 21, 2025) recommend Rydapt for the treatment of aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, and mast cell leukemia (all category 2A).<sup>5</sup> Rydapt is also recommended for the treatment of symptomatic indolent systemic mastocytosis or smoldering systemic mastocytosis if inadequate response, intolerance/no response, or loss of response to first-line therapy with a clinical trial or Ayvakit® (avapritinib tablets) as “useful in certain circumstances” (category 2A).

## POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Rydapt. All approvals are provided for the duration noted below.

- **Rydapt® (midostaurin capsules - Novartis)**

**is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

### FDA-Approved Indications

1. **Acute Myeloid Leukemia.** Approve for 1 year if the patient meets BOTH of the following (A and B):  
A) Patient is  $\geq 18$  years of age; AND  
B) Patient has *FLT3* mutation-positive disease as detected by an approved test.
2. **Aggressive Systemic Mastocytosis.** Approve for 1 year if the patient is  $\geq 18$  years of age.
3. **Mast Cell Leukemia.** Approve for 1 year if the patient is  $\geq 18$  years of age.
4. **Systemic Mastocytosis Associated with Acute Hematologic Neoplasm.** Approve for 1 year if the patient is  $\geq 18$  years of age.

### Other Uses with Supportive Evidence

5. **Indolent Systemic Mastocytosis.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):  
A) Patient is  $\geq 18$  years of age; AND  
B) Patient has symptomatic disease; AND  
C) Patient has tried at least one systemic regimen.  
Note: Example of a systemic regimen includes Ayvakit (avapritinib tablets).
6. **Myeloid or Lymphoid Neoplasms.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):  
A) Patient is  $\geq 18$  years of age; AND  
B) Patient has eosinophilia; AND  
C) Patient meets ONE of the following (i or ii):  
i. Patient has an *FGFR1* rearrangement; OR  
ii. Patient has an *FLT3* rearrangement.

- 7. Smoldering Systemic Mastocytosis.** Approve for 1 year if the patient meets BOTH of the following (A and B):
- A)** Patient is  $\geq 18$  years of age; AND
  - B)** Patient has tried at least one systemic regimen.
- Note: Example of a systemic regimen includes Ayvakit (avapritinib tablets).

## CONDITIONS NOT COVERED

- **Rydapt® (midostaurin capsules (Novartis))**

**is(are) considered experimental, investigational, or unproven for ANY other use(s).**

## REFERENCES

1. Rydapt® capsules [prescribing information]. East Hanover, NJ: Novartis; May 2023.
2. The NCCN Drugs & Biologics Compendium. © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on March 10, 2025. Search term: midostaurin.
3. The NCCN Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology (version 2.2025 – January 27, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on March 10, 2025.
4. The NCCN Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Clinical Practice Guidelines in Oncology (version 1.2025 – February 21, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on March 10, 2025.
5. The NCCN Systemic Mastocytosis Clinical Practice Guidelines in Oncology (version 1.2025 – February 21, 2025). © 2025 National Comprehensive Cancer Network. Available at <http://www.nccn.org>. Accessed on March 10, 2025.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	03/08/2023
Annual Revision	No criteria changes.	03/06/2024
Annual Revision	<p><b>Indolent Systemic Mastocytosis:</b> Indication and criteria were added to "Other Uses with Supportive Evidence" based on National Comprehensive Cancer Network (NCCN) guideline updates.</p> <p><b>Smoldering Systemic Mastocytosis:</b> Indication and criteria were added to "Other Uses with Supportive Evidence" based on NCCN guideline updates.</p>	03/12/2025

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.